Chester County News and Community Website
WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that it will make its investigational therapy NRX-100, a preservative-free formulation of ketamine, available through the U.S. Food and Drug Administration’s …
NRx Pharmaceuticals Expands Access to Investigational Ketamine Therapy for Suicidal Depression Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported its second-quarter financial results and announced a series of significant regulatory, clinical, and corporate developments that strengthen its position in the …
NRx Pharmaceuticals Secures Expanded FDA Fast Track Designation and Strategic Investments Amid Growth Plans Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) will release its second-quarter 2025 financial results after market close on Thursday, August 14, followed by a 4:30 p.m. ET conference call …
NRx Pharmaceuticals to Report Q2 2025 Results on August 14 Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has achieved a significant milestone in the development of its antidepressant drug, NRX-100 (Ketamine). On September 24, 2024, the company announced that the …
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently received attention in an article on Psychiatrist.com, which discussed the potential of its pipeline products, NRX-100 and NRX-101, in addressing bipolar depression …
NRx Pharmaceuticals’ Innovative Treatments for Depression Gain Spotlight Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has released its financial results for the second quarter and year-to-date ending June 30, 2024, along with a comprehensive business update. The company …
NRx Pharmaceuticals Reports Second Quarter and Year-to-Date 2024 Financial Results and Business Update Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently secured up to $16 million in convertible debt financing from an institutional investor. The company plans to use the funds to …
NRx Pharmaceuticals Secures $16 Million in Convertible Debt Financing Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that the U.S. Food and Drug Administration (FDA) has provided positive feedback and alignment on its proposed initial Pediatric Study Plan …
FDA Aligns with NRx Pharmaceuticals on Pediatric Study for Suicidal Depression Treatment Read More
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has received a favorable ruling from a Utah arbitrator, allowing the company to move forward with its planned spinoff of 49% of …
NRx Pharmaceuticals Wins Arbitration to Proceed with HOPE Therapeutics Spinoff Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently announced plans to file two New Drug Applications (NDAs) in 2024. The filings, supported by advice from regulatory counsel including former …
NRx Pharmaceuticals Plans to File Two New Drug Applications in 2024 Read More